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1 ABSTRACT 
 
2 Objectives 
 
3 The study aimed to (i) assess whether higher vasti (VASTI), gluteus medius (GMED), gluteus maximus 
 
4 (GMAX) and gluteus minimus (GMIN) forces are associated with participant characteristics (lower age, male 
 
5 gender) and clinical characteristics (lower radiographic disease severity, lower symptom severity and higher 
 
6 walking  speed);  and  (ii)  determine  whether  hip  and  knee  muscle  forces  are  lower  in  people  with 
 
7 patellofemoral (PFJ) osteoarthritis (OA) compared to those without PFJ OA. 
 
8 Design 
 
9 Sixty participants with PFJ OA and 18 (asymptomatic, no radiographic OA) controls ≥40 yrs were recruited 
 
10 from the community or via referrals. A three-dimensional musculoskeletal model was used in conjunction 
 
11 with optimization theory to calculate lower-limb muscle forces during walking. Associations of peak muscle 
 
12 forces with participant and clinical characteristics were conducted using Spearman’s rho or independent t- 
 
13 tests and between-group comparisons of mean peak muscle forces performed with walking speed as a 
 
14 covariate. 
 
15 
 
16 Results 
 
17 Peak muscle forces were not significantly associated with participant, symptomatic or radiographic-specific 
 
18 characteristics. Faster walking speed was associated with higher VASTI muscle force in the PFJ OA (rs=0.499; 
 
19 p<0.001) and control groups (rs=0.769; p<0.001) and higher GMAX muscle force (rs=0.579; p=0.012) in the 
 
20 control group only. Individuals with PFJ OA (n=60) walked with lower GMED and GMIN muscle forces than 
 
21 controls (n=18): GMED, mean difference 0.15 [95% confidence interval: 0.01 to 0.29] body weight (BW); 
 
22 GMIN, 0.03 [0.01 to 0.06] BW. No between-group differences were observed in VASTI or GMAX muscle 
 
23 force: VASTI, 0.10 [-0.11 to 0.31] BW; GMAX, 0.01 [-0.11 to 0.09] BW. 
 
24 
 
25 Conclusion 
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1 Individuals  with  PFJ  OA  ambulate  with  lower  peak  hip  abductor  muscle  forces  than  their  healthy 
 
2 counterparts. 
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1 INTRODUCTION 
 
2 Patellofemoral joint (PFJ) osteoarthritis (OA) is a common disease, affecting approximately two thirds of 
 
3 those with symptomatic knee OA [1, 2]. Importantly, the PFJ is also a major source of knee pain and 
 
4 reduced physical function [2], exceeding the contribution from the tibiofemoral joint [3, 4]. Despite its 
 
5 prevalence  and  associated  morbidity,  little  is  known  about  the  features  of  people  with  PFJ  OA.  The 
 
6 biomechanics of the PFJ are distinct from the tibiofemoral joint and hence, interventions that have been 
 
7 designed to reduce pain and improve function in those with tibiofemoral disease may be inappropriate for 
 
8 those with predominant PFJ OA. Given the heterogeneity of aetiology, symptomatic presentation and 
 
9 natural history of knee OA, it appears as though optimal interventions should consider targeting the salient 
 
10 features associated with the compartmental involvement [5]. The local PFJ biomechanics, and in particular 
 
11 alignment of the patella within the femoral trochlea, is associated with PFJ OA [6, 7] and its progression [8]. 
 
12 Consequently,  the  few  trials  that  evaluated  targeted  interventions  for  PFJ  OA  focused  on  addressing 
 
13 patellar alignment via passive techniques such as taping [6, 9] and bracing [10]. Such treatments resulted in 
 
14 positive immediate effects, but limited longer-term effects. It is possible that individuals exhibit more 
 
15 global impairments (e.g., thigh and hip muscle dysfunction) that should also be addressed in targeted 
 
16 interventions. 
 
17 
 
 
18 While there is a dearth of information on thigh and hip muscle dysfunction in PFJ OA, similarities in pain 
 
19 characteristics and the likely relationship between PFJ pain syndrome and incident PFJ OA imply that 
 
20 analogies may be drawn from the greater body of knowledge in PFJ pain syndrome. Impairments in hip 
 
21 muscle strength, specifically abduction, extension and external rotation, are features of individuals with PFJ 
 
22 pain syndrome [11]. Furthermore, quadriceps weakness, measured via dynamometry, has been identified 
 
23 as a feature of PFJ OA [12] and is associated with progression of OA in the PFJ [13]. The PFJ is intimately 
 
24 related to  quadriceps function and consequently, individuals exhibiting pain arising from the PFJ  may 
 
25 modify their walking behaviour in order to reduce quadriceps force [14]. However, it is not known whether 
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1 individuals  with  PFJ  OA  ambulate  with  lower  quadriceps  and  hip  muscle  forces  than  their  healthy 
 
2 counterparts. 
 
 
3 
 
4 Biomechanical  evaluations  of  people  with  PFJ  pain  syndrome  are  frequently  performed  to  identify 
 
5 impairments  in  gait.  While  many  studies  have  calculated  net  joint  torques  and  powers  to  evaluate 
 
6 biomechanical  load,  such  measures  do  not  provide  quantitative  information  about  the  function  of 
 
7 individual muscles. Computational musculoskeletal modelling [15] may be used to estimate muscle forces 
 
8 during activities such as gait. Therefore, the aims of this study were to (i) assess whether higher vasti 
 
9 (VASTI),  gluteus  medius  (GMED),  gluteus  maximus  (GMAX)  and  gluteus  minimus  (GMIN)  forces  are 
 
10 associated  with  participant  characteristics  (lower  age,  male  gender)  and  clinical  characteristics  (lower 
 
11 radiographic  disease  severity,  lower  symptom  severity  and  higher  walking  speed);  and  (ii)  determine 
 
12 whether hip and knee muscle forces are lower in people with PFJ OA compared to those without PFJ OA. 
 
13 
 
14 MATERIALS AND METHODS 
 
15 Participants 
 
16 Sixty people with symptomatic PFJ OA and 18 controls (no knee pain and no radiographic OA) participated 
 
17 in this study. People with predominant lateral PFJ OA were a subgroup of a larger cohort recruited for a 
 
18 randomised  controlled  trial  [16]  from  advertisements  in  the  community  and  via  medical  and  health 
 
19 practitioners’ referrals. Inclusion criteria included: (i) aged at least 40 years; (ii) anterior- or retro-patellar 
 
20 knee pain severity ≥ 4 on an 11 point numerical pain scale during at least two activities that load the PFJ 
 
21 (e.g. stair ambulation, squatting and/or rising from sitting); (iii) pain during these activities present on most 
 
22 days during the past month; and (iv) Kellgren and Lawrence (K/L) grading of the lateral PFJ ≥ 2 [17] from 
 
23 skyline views [18] and overall K/L grading (for the tibiofemoral joint) ≤ 2 from postero-anterior views. The 
 
24 control participants were also recruited from the community via advertisements placed in local newspapers 
 
25 and  posters.  They  had  no  knee  or  other  lower-limb  complaints,  were  physically  active  and  had  no 
 
26 radiographic OA (K/L grade ≤ 1 in all compartments). Exclusion criteria included: (i) concomitant pain from 
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1 other joints affecting lower-limb function; (ii) recent knee injections (prior 3 months); (iii) body mass index 
 
2 ≥  35  kg.m-2;  (iv)  knee  or  hip  arthroplasty  or  osteotomy;  (v)  physical  inability  to  undertake  testing 
 
3 procedures; (vi) neurological or other medical conditions; and (vii) inability to understand written and 
 
4 spoken English. Participants underwent telephone and physical screening by a single researcher (JL) prior to 
 
5 radiographs. Approval was granted from the University of Melbourne Human Research Ethics Committee, 
 
6 and all participants provided written informed consent. Information on age and gender were collected from 
 
7 the participants and body mass index (BMI) calculated from weight and height measurements. 
 
8 
 
9 Radiographic disease severity 
 
10 Radiographic severity of tibiofemoral joint OA was assessed from a semi-flexed, postero-anterior weight- 
 
11 bearing short film radiograph with the feet externally rotated by 10° using the K/L grading system [17]. 
 
12 Radiographic  severity of PFJ OA  was  assessed  from  weightbearing skyline  radiographs,  with the  knee 
 
13 positioned at 30-40° knee flexion [19], using the K/L grades applied to the PFJ joint[18]. All grading was 
 
14 performed by two investigators (KMC and RSH), with inter-rater reliability (κ) for grading tibiofemoral joint 
 
15 and PFJ radiographic OA on a subset of 39 participants ranging from 0.745-0.843. 
 
16 
 
17 Knee osteoarthritis symptoms 
 
18 The Knee Injury and Osteoarthritis Outcome Score (KOOS) was used to assess patient reported outcomes 
 
19 [20]. The KOOS has five subscales: pain, symptoms, function in activities of daily living (ADL), function in 
 
20 sport and recreation (sport/rec), and knee-related quality of life (QoL). Each of the five subscales addresses 
 
21 symptoms over the previous week, and a normalised score (100 represents no symptoms and 0 represents 
 
22 maximum symptoms) is calculated for each subscale from the original Likert responses. The KOOS is reliable 
 
23 [20] and has face validity for people with PFJ OA symptoms. Thus, in the absence of any PFJ OA-specific 
 
24 outcome measures, the KOOS was deemed to be appropriate for this study. 
 
25 
 
26 Calculation of muscle forces 
 
 
6 25-Jun-12 
1 A  musculoskeletal  computer  model,  implemented  in  OpenSim  [21],  was  used  to  calculate  lower-limb 
 
2 muscle forces. Estimates of lower-limb muscle forces for walking obtained using this model have been 
 
3 evaluated  previously  [22,  23].  The  skeleton  was  represented  as  an  8-segment,  21-degree-of-freedom 
 
4 linkage (Figure 1A). The head, arms, and torso were modelled as a single rigid body, which articulated with 
 
5 the pelvis via a ball-and-socket back joint. Each hip was modelled as a ball-and-socket joint, and each knee 
 
6 as   a   modified   one-degree-of-freedom   planar   joint.   Each   talo-crural   joint,   subtalar   joint   and 
 
7 metatarsophalangeal joint was modelled as a hinge. The lower limbs and trunk were actuated by 92 
 
8 muscle-tendon units, each represented as a line segment joining an origin point on the proximal segment 
 
9 to an insertion point on the distal segment. The paths of muscles that wrapped over underlying structures 
 
10 were modelled using via points [21]. Each muscle-tendon unit was modelled as a three-element Hill-type 
 
11 muscle  in  series  with  an  elastic  tendon  [24]  (Figure  1B).  For  each  participant,  body-segment  inertial 
 
12 properties and muscle-tendon properties were scaled from a generic adult model [21] using body mass and 
 
13 segment dimensions as scaling factors, respectively. 
 
14 
 
15 Experimental gait data were collected in the Biomotion Laboratory, Department of Mechanical Engineering, 
 
16 University of Melbourne, Australia. Three force plates embedded in the floor of the laboratory were used 
 
17 to record ground reaction forces under both legs at a sampling frequency of 1080 Hz (Advanced Mechanical 
 
18 Technology Inc., Watertown, MA, USA). All ground reaction force data were low-pass filtered using a 
 
19 fourth-order Butterworth filter with a cut-off frequency of 60 Hz. Kinematic data were recorded using a 
 
20 video-based, motion capture system (Vicon, Oxford Metrics, Oxford, UK) with nine cameras sampling at a 
 
21 frequency of 120 Hz. Reflective markers were attached at specific locations on the patient’s trunk, pelvis, 
 
22 both upper limbs and both lower limbs; specifically at the C7 spinous process, acromioclavicular joint, 
 
23 lateral  elbow  epicondyle,  dorsal  aspect  of  the  wrist,  anterior  superior  iliac  spine,  mid-point  between 
 
24 posterior superior iliac spines, anterior mid and distal thigh, lateral mid and distal thigh, lateral femoral 
 
25 epicondyle, proximal and distal anteromedial shank, mid lateral shank, heel, lateral malleolus, lateral and 
 
26 medial  midfoot,  medial  aspect  of  first  metatarsal-phalangeal  joint,  lateral  aspect  of  fifth  metatarsal- 
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1 phalangeal joint, and dorsal aspect of first toe. Muscle electromyographic (EMG) data were collected to 
 
2 enable evaluation of the temporal consistency between muscle force estimates and muscle activations 
 
3 during walking. The EMG data were recorded using pairs of Ag/AgCl surface electrodes (Motion Laboratory 
 
4 Systems, Baton Rouge, LA, USA) mounted on the skin over the gluteus maximus, gluteus medius, medial 
 
5 and lateral vasti, hamstrings, rectus femoris, gastrocnemius and soleus. EMG data were sampled at 1080 
 
6 Hz. The raw EMG signal was full-wave rectified and a Teager-Kaiser Energy (TKE) filter was then applied to 
 
7 the rectified EMG signal to improve the onset and offset detection [25]. Cross-talk was minimised by 
 
8 following published recommendations regarding the placement of surface electrodes [26]. 
 
9 
 
10 An initial static trial was performed with the participant standing in a neutral pose and additional markers 
 
11 placed on the left and right medial femoral epicondyles and medial malleoli. Following the static trial, 
 
12 participants performed three gait trials at a self-selected speed on a 10 m level walkway. Each participant’s 
 
13 walking speed was calculated from the kinematic data by measuring the average horizontal velocity of a 
 
14 marker mounted on the posterior aspect of the pelvis. 
 
15 
 
16 A  single  representative  gait  trial  for  each  participant  was  chosen  for  analysis,  and  all  analyses  were 
 
17 performed in OpenSim [21]. An inverse kinematics problem was solved to determine the model joint angles 
 
18 that best matched the marker data obtained from the gait analysis experiment [27]. The net joint torques 
 
19 were calculated using a traditional inverse dynamics approach [28]. A static optimization problem was then 
 
20 solved to decompose the joint torques into individual muscle forces by minimizing the sum of the squares 
 
21 of the muscle activations [29, 30]. The optimization solution was constrained to the force-length-velocity 
 
22 surface of each muscle [30] (Figure 1C). 
 
23 
 
24 The lower-limb muscle forces of interest were: (1) GMAX; (2) GMED; (3) GMIN; and VASTI (vastus lateralis, 
 
25 intermedius and medialis combined). For each muscle group, peak force during the stance phase was 
 
26 identified and then normalised to the participant’s body weight (BW). 
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1 
 
2 Statistical analysis 
 
3 All analyses were performed using the Statistical Package for the Social Sciences (PASW Statistics 18, SPSS 
 
4 Inc.,  Chicago,  IL)  with  an  alpha  level  of  0.05.  Between-group  differences  in  participant  and  clinical 
 
5 characteristics were assessed using Student’s t-tests or chi square tests, as appropriate. The associations 
 
6 between mean peak muscle forces with participant and clinical characteristics were mostly conducted using 
 
7 Pearson’s r correlation coefficient. For the radiographic disease severity (ordinal data), the associations 
 
8 were calculated with the Spearman’s rho correlation coefficients, while independent t-test were used for 
 
9 gender. Between-group differences in mean peak muscle forces were analysed with walking-speed as a 
 
10 covariate using an Analysis of Covariance (ANCOVA). The sample size (60 PFJ OA patients and 18 controls) 
 
11 provides >90% power to detect a between-group difference in muscle force of 10%, with a standard 
 
12 deviation of 10%. 
 
13 
 
14 RESULTS 
 
15 There were no statistically significant differences for age, height or gender between the PFJ OA group 
 
16 (N=60) and the control group (N=18) (Table 1). Those with PFJ OA were heavier than the control individuals, 
 
17 with a greater BMI. In line with our eligibility criteria, the most prevalent radiographic grade (Table 2) was 
 
18 K/L grade 2 in the lateral PFJ and in the tibiofemoral joint. 
 
19 
 
20 Self-selected walking speed was not different between the PFJ OA group and the control group (mean 
 
21 difference [95% confidence interval]: 0.03 [-0.04 to 0.11]) (Table 1). However in the control group, walking 
 
22 speed was significantly correlated with VASTI (r=0.727; p=0.001) and GMAX (r=0.593; p=0.009) peak forces, 
 
23 but age was not statistically significantly correlated with peak muscle forces (Table 3). In the PFJ OA group, 
 
24 walking  speed was  significantly  correlated  with  VASTI peak  force (r=0.495; p<0.001),  but  age  did not 
 
25 statistically significantly correlate with peak muscle forces (Table 3). There was no significant effect of 
 
26 gender on VASTI (0.12: [-0.11 to 0.34], GMAX (-0.03: [-0.12 to 0.06]), GMED (-0.05: [-0.18 to 0.08]) or GMIN 
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1 (-0.01: [-0.03 to 0.02]) peak muscle force. Radiographic disease severity in the tibiofemoral joint and lateral 
 
2 PFJ were not statistically significantly correlated with peak muscle forces in the PFJ OA group (Table 3). 
 
3 Additionally, no statistically significant correlations were observed between any subscale of the KOOS and 
 
4 peak muscle forces in the PFJ OA group (Table 3). 
 
5 
 
6 There were differences in the peak muscle forces for GMED and GMIN between the PFJ OA group and 
 
7 control  group  (Table  4  and  Figure  2).  Individuals  with  PFJ  OA  walked  with  lower  GMED  (0.15  [95% 
 
8 confidence interval: 0.01 to 0.29] BW); and GMIN (0.03 [0.01 to 0.06] BW) muscle forces than controls. No 
 
9 between-group differences were observed in VASTI or GMAX muscle force: VASTI, 0.10 [-0.11 to 0.31] BW; 
 
10 GMAX, 0.01 [-0.11 to 0.09] BW. Ensemble averages across the stance phase of gait for normalised muscle 
 
11 forces are presented in Figure 2. Model predictions of muscle forces were in temporal agreement with 
 
12 measured  EMG  activity  (Supplementary  Figure  1),  providing  a  qualitative  evaluation of  the  modelling 
 
13 approach used in this study. 
 
14 
 
15 DISCUSSION 
 
16 Awareness of the importance of the PFJ in the clinical picture of knee OA is increasing due to its prevalence 
 
17 and contribution to  knee OA  symptoms.  Knowledge  of  impairments associated  with  this subgroup of 
 
18 people with knee OA will advance our understanding of this chronic disease. We found that people with PFJ 
 
19 OA  walk  with  reduced  hip  abductor  muscle  forces,  compared  with  pain-free,  aged-matched  controls. 
 
20 Specifically, peak GMED and GMIN muscle forces were approximately 11% lower than pain-free individuals. 
 
21 The variability in GMAX, GMED, GMIN and VASTI peak muscle forces was not related to radiographic 
 
22 disease severity, knee osteoarthritis symptom severity or other participant characteristics. 
 
23 
 
24 To our knowledge, this is the first study to estimate lower-limb muscle forces in a cohort of people with PFJ 
 
25 OA. Our calculated peak VASTI muscle force was higher (1.16 [95% confidence interval 1.06 to 1.26] BW) 
 
26 than those reported for a single TKA patient walking with an instrumented knee (0.73 BW)  [22]. The 
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1 temporal patterns of lower-limb muscle forces were similar between the two studies. Since walking speed 
 
2 is known to influence the magnitude of lower-limb muscle forces [15], it is possible that differences in 
 
3 walking speed between the current study (1.37 [1.30 to 1.44] m.s-1  , Table 1) and that of Kim et al. [22] 
 
4 (1.24 (standard deviation 0.33) m.s-1) partially explain some of the differences observed in the calculated 
 
5 values of muscle forces. Furthermore, in the study by Kim and colleagues [22], the patient had end stage 
 
6 OA warranting a total joint replacement, whereas our study contained individuals with no greater than K/L 
 
7 grade 2 radiographic OA. Thus, differences in peak VASTI force may be partially accounted for by the 
 
8 disparity in the patient population. It is difficult to directly compare our data with that from a previous 
 
9 study [31], where lower-limb muscle forces were computed for a cohort of younger individuals with PFJ 
 
10 pain syndrome, because an EMG-driven modelling approach was used and all muscle force data were 
 
11 normalised by the peak isometric force of each muscle. 
 
12 
 
13 Our finding of lower peak GMED and GMIN forces in those with PFJ OA is consistent with emerging 
 
14 evidence that hip muscle dysfunction is a dominant feature of individuals with PFJ pain syndrome [11]. The 
 
15 GMED and GMIN primarily contribute to hip abduction moments during walking [32]. Since the cross- 
 
16 sectional nature of the study design precludes knowledge of the temporal relationship between lower 
 
17 GMED and GMIN muscle forces and PFJ OA development or progression, further studies are required to 
 
18 confirm the clinical implications of our findings. Our results indicate that individuals with PFJ OA exhibit 
 
19 altered function that is isolated to the more proximal segments, providing further evidence for a potential 
 
20 link to PFJ pain syndrome. 
 
21 
 
22 We found no difference in peak VASTI and GMAX muscle force in those with and without PFJ OA. Our 
 
23 results contrast with previous studies that have measured peak isometric knee-extensor torque using a 
 
24 dynamometer  [12,  13];  however,  there  is  an  imprecise  relationship  between  knee-extensor  torque 
 
25 measured in an open-kinetic-chain task and peak muscle force utilised during a functional activity such as 
 
26 walking. Our results may reflect variability in gait adaptations during walking in our population of people 
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1 with symptomatic PFJ OA. Notably, there was a non-significant lower peak VASTI muscle force (~8%) in our 
 
2 PFJ OA patients, which may reflect that some individuals are likely to walk with lowered VASTI force, 
 
3 potentially as a pain-relieving strategy. It is also possible that deficits in the coordination (e.g. onset timing) 
 
4 of the medial and lateral components of the vasti may be more important than the total peak VASTI force 
 
5 in individuals with PFJ OA, in a similar manner to PFJ syndrome [33]. Future studies might evaluate VASTI 
 
6 and GMAX muscle forces in functional tasks, such as stair ambulation, which subject the PFJ to greater load, 
 
7 or evaluate the relative coordination of the medial and lateral vasti. 
 
8 
 
9 Peak muscle  forces  were mostly  not  correlated with  participant,  symptomatic  or  radiographic-specific 
 
10 characteristics, implying that muscle forces alone do not reflect the severity of radiographic or symptomatic 
 
11 disease. Although previous investigations of individuals with predominantly tibiofemoral joint OA have 
 
12 observed associations between radiographic OA severity and kinematics at the hip [34], these observations 
 
13 were only significant for those with severe radiographic OA (K/L grade 4). Similarly, many authors have 
 
14 noted a difference in the knee adduction moment only in those with more severe radiographic tibiofemoral 
 
15 disease [35]. It appears likely that changes in gait mechanics at the knee may be associated with the 
 
16 structural changes that accompany the OA disease process, such as altered frontal plane alignment. Since 
 
17 our cohort was restricted to those with a K/L grade ≤ 2, it is not surprising that radiographic disease severity 
 
18 was not associated with peak muscle loading during gait. Although faster walking speed was associated 
 
19 with a higher peak VASTI muscle force in the PFJ OA and control groups and a higher peak GMAX muscle 
 
20 force in the control group, walking speed was controlled for statistically and therefore the between-group 
 
21 differences in muscle force noted in the current study were not attributable to differences in walking 
 
22 speed. 
 
23 
 
24 It is not possible to discern the function of individual muscles from net joint torques alone, simply because 
 
25 a given joint torque can be satisfied by an infinite combination of muscle forces. Musculoskeletal modelling 
 
26 represented the only practicable method for determining lower-limb muscle forces in the current study. 
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1 However, there are several limitations and assumptions inherent in this modelling approach; for example, 
 
2 the physiological properties prescribed for the muscle-tendon actuators included in the model (e.g., peak 
 
3 isometric muscle force and the corresponding muscle-fiber length and tendon rest length; see Figure 1B). 
 
4 Importantly, the present study assumed the same unscaled muscle-tendon parameters across both the PFJ 
 
5 OA and control population and hence, any relative differences in muscle force predictions are attributable 
 
6 mostly to differences in the experimental gait data and not the parameters assumed in the model. We also 
 
7 elected to analyse synergistic groups of muscles (i.e., GMAX, GMED, GMIN, VASTI) and did not attempt to 
 
8 partition calculated forces onto the various components of these muscle groups (e.g., vastus medialis vs 
 
9 intermedius vs lateralis within VASTI). Several studies have shown that our approach of obtaining muscle 
 
10 force estimates for synergistic groups of muscles is relatively insensitive to changes in the values assumed 
 
11 for peak isometric muscle force (or physiological cross-sectional area) [36-38]. Despite the aforementioned 
 
12 limitations, the inverse-dynamics-based optimisation approach employed in the current study is robust, 
 
13 computationally efficient, and has been used extensively to estimate lower-limb muscle forces in walking 
 
14 [15, 39, 40]. Furthermore, indirect evidence is available to support the validity of predicting lower-limb 
 
15 muscle forces during walking using the approach taken in the present paper [22]. Lastly, previous studies 
 
16 have shown temporal agreement between predicted lower-limb muscle forces and recorded EMG [41], and 
 
17 this relationship was also demonstrated in the present study for a representative subject (Supplementary 
 
18 Figure 1). 
 
19 
 
20 A final limitation relates to the participant characteristics of the control group. Although we attempted to 
 
21 recruit participants who were matched on variables likely to influence muscle forces, the control group was 
 
22 lighter and trending towards being younger. We controlled for body weight by normalising all muscle force 
 
23 data, and age was not associated with the muscle force data. In order to be included in the control group, 
 
24 participants had to exhibit a K/L grade ≤ 1. While this is usually accepted as a criterion for no OA, it is 
 
25 possible that participants in the control group had some early/mild OA that may have affected their gait 
 
26 pattern. It is also possible that some participants in either group may have had coexisting hip OA. However, 
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1 the control group were required to have no knee pain and all participants were required to report no 
 
2 hip/groin or lower-back symptoms. The sample size for the control group was chosen to be as large as 
 
3 could be practically achieved within the time and resource constraints, and consequently the control group 
 
4 included much fewer participants (N=18) than our PFJ OA cohort (N=60). This difference reflected the 
 
5 difficulties in recruiting an older population from the general community with no knee or other lower-limb 
 
6 complaints, who were physically active with no radiographic knee OA, and who had the time and inclination 
 
7 to attend for both radiographic and biomechanical evaluation. Nevertheless, our sample size calculations 
 
8 revealed that we had sufficient power, despite the discrepant sample sizes. 
 
9 
 
10 This study is the first to investigate the walking mechanics of individuals with predominant PFJ OA. Our 
 
11 findings indicate that individuals with PFJ OA ambulate with lower peak hip abductor muscle force than 
 
12 their healthy counterparts. It is not known whether a lower hip abductor muscle force contributes to, or is 
 
13 a consequence of, the PFJ OA disease process. 
 
14 
 
15 
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1 Table 1: Participant and clinical characteristics: patellofemoral osteoarthritis and control groups 
 
 Pain-free 
 
Control † 
 
N = 18 
Patellofemoral 
 
osteoarthritis † 
 
N = 60 
Mean difference 
 
[95% CI] 
p value 
Age (yr) 53 (7) 58 (10) 4 [-0.8 to 10] 0.096 
 
Height (m) 
 
1.65 (0.08) 
 
1.69 (0.09) 
 
0.03 [-0.06 to 0.08] 
 
0.186 
 
Weight (kg) 
 
66 (12) 
 
78 (13) 
 
12 [5 to 19] 
 
0.001* 
BMI (kg.m-2) 
 
24.1 (3.4) 
 
27.5 (3.7) 
 
3.3 [1.4 to 5.3] 
 
0.001* 
 
Gender (n(%)) 
 
14 female (78%) 
 
39 female (65%) 
 
- 
 
‡0.236 
 
KOOS-pain 
 
- 
 
63 (15) 
 
- 
 
- 
 
KOOS-symptoms 
 
- 
 
61 (16) 
 
- 
 
- 
 
KOOS-ADL 
 
- 
 
70 (16) 
 
- 
 
- 
 
KOOS-Sport/Rec 
 
- 
 
41 (22) 
 
- 
 
- 
 
KOOS-QoL 
 
- 
 
12 (16) 
 
- 
 
- 
Walking speed (m.s-1) 
 
1.34 (0.13) 
 
1.37 (0.17) 
 
0.03 [-0.04 to 0.11] 
 
0.369 
2 † all values are mean (SD) unless indicated; CI = confidence interval; ‡ χ2; * Denotes statistically significant, p < 0.05 
 
3 BMI = body mass index 
 
4 KOOS = Knee Injury and Osteoarthritis Outcome Score [20] (100 =no symptoms - 0 = maximum symptoms) 
 
5 KOOS-pain = pain subscale of the KOOS 
 
6 KOOS-symptoms =symptoms subscale of the KOOS 
 
7 KOOS-ADL = activities of daily living subscale of the KOOS 
 
8 KOOS-Sport/Rec =Sport and recreation subscale of the KOOS 
 
9 KOOS-QoL =Knee-related quality of life subscale of the KOOS 
 
10 
 
11 
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1 Table 2: Radiographic disease severity for the patellofemoral osteoarthritis group (n = 60) 
 
Grade 0 
 
n (%) 
Grade 1 
 
n (%) 
Grade 2 
 
n (%) 
Grade 3 
 
n (%) 
Grade 4 
 
n (%) 
 
Tibiofemoral (K/L) 14 (23%) 18 (30%) 28 (47%) 0 0 
 
Lateral patellofemoral (K/L)† 0 0 39 (65%) 11 (18%) 10 (17%) 
 
2 K/L Kellgren and Lawrence scale [17]: 0 = no osteoarthritis ; 4 = severe osteoarthritis 
 
3 K/L† Kellgren and Lawrence scale adapted for patellofemoral joint [18] 
 
4 
 
5 
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1 Table  3:  Univariate  associations  between  normalised  peak  muscle  forces,  participant  and  clinical 
 
2 characteristics 
 
GMAX GMED GMIN VASTI 
 
Control group (n=18) 
 
Age (yr) r -0.195 -0.96 -0.84 106 
 
p 0.439 0.705 0.739 0.676 
 
Walking speed (m.s-1) r 0.593 0.076 0.047 0.727 
 
p 0.009* 0.764 0.853 0.001* 
 
PFJ OA group (n=60) 
 
Age (yr) R -0.86 -0.138 -0.125 -0.174 
 
P 0.514 0.295 0.340 0.185 
 
KOOS-pain R 0.081 0.050 0.023 0.103 
 
p 0.539 0.704 0.859 0.435 
 
KOOS-symptoms r -0.026 -0.029 -0.041 0.069 
 
p 0.843 0.826 0.754 0.598 
 
KOOS-ADL r -0.045 -0.053 -0.062 0.133 
 
p 0.734 0.685 0.637 0.311 
 
KOOS-Sport/Rec r -0.018 -0.050 -0.056 0.261 
 
p 0.892 0.702 0.669 0.097 
 
KOOS-QoL r -0.059 -0.036 -0.029 0.111 
 
p 0.652 0.784 0.824 0.396 
 
Walking speed (m.s-1) r 0.145 0.090 0.040 0.495 
 
p 0.267 0.494 0.763 <0.001* 
 
Tibiofemoral (K/L)‡ rho -0.040 0.114 0.108 0.058 
 
p 0.763 0.385 0.413 0.660 
 
Lateral patellofemoral (K/L) ‡† rho -0.084 0.104 0.060 -0.072 
 
p 0.524 0.430 0.649 0.586 
 
3 Correlations using Pearson’s r correlation co-efficient unless indicated 
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1 ‡Correlations using Spearman’s rho correlation co-efficient * Denotes statistically significant, p < 0.05 
 
2 GMAX = gluteus maximus 
 
3 GMED = gluteus medius 
 
4 GMIN= gluteus minimus 
 
5 VASTI = vastus medialis, vastus lateralis and vastus intermedialis 
 
6 KOOS = Knee Injury and Osteoarthritis Outcome Score [20] (100=no symptoms – 0=maximum symptoms) 
 
7 KOOS-pain = pain subscale of the KOOS 
 
8 KOOS-symptoms =symptoms subscale of the KOOS 
 
9 KOOS-ADL = activities of daily living subscale of the KOOS 
 
10 KOOS-Sport/Rec =Sport and recreation subscale of the KOOS 
 
11 KOOS-QoL =Knee-related quality of life subscale of the KOOS 
 
12 K/L Kellgren and Lawrence scale [17]: 0 = no osteoarthritis ; 4 = severe osteoarthritis 
 
13 K/L† Kellgren and Lawrence scale adapted for patellofemoral joint [18] 
 
14 
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1 Table 4: Between group comparisons of normalised peak muscle forces between symptomatic PFJ OA 
 
2 and control groups 
 
Pain-free 
 
Control † 
 
N = 18 
Patellofemoral 
 
osteoarthritis † 
 
N = 60 
Mean difference † P 
 
GMAX (BW) 0.69 [0.61 to 0.78] 0.70 [0.66 to 0.75] 0.01 [-0.11 to 0.09] 0.796 
 
GMED (BW) 1.41 [0.28 to 1.53] 1.26 [1.19 to 1.33] 0.15 [0.01 to 0.29] 0.041* 
GMIN (BW) 0.24 [0.22 to 0.26] 0.21 [0.20 to 0.22] 0.03 [0.01 to 0.06] 0.013* 
VASTI (BW) 1.26 [1.08 to 1.44] 1.16 [1.06 to 1.26] 0.10 [-0.11 to 0.31] 0.355 
 
3 † all values are mean *95% confidence interval+ and adjusted for walking speed; * Denotes statistically significant, p < 
 
4 0.05 
 
5 BW = body weight 
 
6 GMAX = gluteus maximus 
 
7 GMED = gluteus medius 
 
8 GMIN= gluteus minimus 
 
9 VASTI = vastus medialis, vastus lateralis and vastus intermedialis 
 
10 
 
11 
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Figure Legends 
 
 
 
 
 
 
FIGURE CAPTIONS 
 
 
Fig. 1:   Three-dimensional musculoskeletal model used in the present study. (A) The skeleton was 
modeled as a multi-body linkage comprised of 21 degrees of freedom, and was actuated by 
92 muscle-tendon units. (B) Each muscle-tendon actuator was represented as a Hill-type 
muscle (active and passive) in series with an elastic tendon. (C) The active force, FM, 
developed by muscle was governed by its force-length-velocity surface, defined by the 
muscle's length, LM, and velocity of contraction, VM. 
 
 
 
 
 
Fig. 2:   Muscle forces during the stance phase of walking. Mean (±1SD) data are presented for the 
control (solid line (mean) with dark grey shading (SD); N=18) and PF JOA (dashed line (mean) 
with light grey shading (SD); N=60) populations. Muscle symbols appearing in the graphs are: 
GMAX  (gluteus  maximus),  GMED  (gluteus  medius),  GMIN  (gluteus  minimus)  and  VASTI 
(vastus lateralis, vastus medialis and vastus intermedius heads). IFS, IFO, CFS and CFO signify 
ipsilateral foot-strike, ipsilateral foot-off, contralateral foot-strike and contralateral foot-off, 
respectively. 
Figure Legends 
 
 
 
 
 
 
Supp Figure:      Model predicted muscle forces and experimental EMG signals for a representative 
PFJ OA subject (n=1; Body weight = 59kg) for walking at a self-selected speed of 1.34 
m/s. Data are shown from foot strike to foot strike; shaded region represents the 
stance  phase.  Muscle  symbols  appearing  in  the  graphs  are:  GMAX  (gluteus 
maximus), GMED (gluteus medius), HAMS (hamstrings; semimembranous, 
semitendinosus, biceps femoris long head and biceps femoris short head combined), 
RF (rectus femoris), VASTI (vastus medialis, vastus intermedius and vastus lateralis 
combined); GAS (gastrocnemius) and SOL (soleus). Muscle electromyographic (EMG) 
activity was recorded using pairs of Ag/AgCl surface electrodes (Motion Laboratory 
Systems, Baton Rouge, LA, USA) mounted on the skin over the gluteus maximus, 
gluteus medius, vastus lateralis, medial hamstrings (semitendinosus), rectus femoris, 
medial gastrocnemius and soleus. 
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1 ABSTRACT 
 
2 Objectives 
 
3 The study aimed to (i) assess whether higher vasti (VASTI), gluteus medius (GMED), gluteus maximus 
 
4 (GMAX) and gluteus minimus (GMIN) forces are associated with participant characteristics (lower age, male 
 
5 gender) and clinical characteristics (lower radiographic disease severity, lower symptom severity and higher 
 
6 walking  speed);  and  (ii)  determine  whether  hip  and  knee  muscle  forces  are  lower  in  people  with 
 
7 patellofemoral (PFJ) osteoarthritis (OA) compared to those without PFJ OA. 
 
8 Design 
 
9 Sixty participants with PFJ OA and 18 (asymptomatic, no radiographic OA) controls ≥40 yrs were recruited 
 
10 from the community or via referrals. A three-dimensional musculoskeletal model was used in conjunction 
 
11 with optimization theory to calculate lower-limb muscle forces during walking. Associations of peak muscle 
 
12 forces with participant and clinical characteristics were conducted using Spearman’s rho or independent t- 
 
13 tests and between-group comparisons of mean peak muscle forces performed with walking speed as a 
 
14 covariate. 
 
15 
 
16 Results 
 
17 Peak muscle forces were not significantly associated with participant, symptomatic or radiographic-specific 
 
18 characteristics. Faster walking speed was associated with higher VASTI muscle force in the PFJ OA (rs=0.499; 
 
19 p<0.001) and control groups (rs=0.769; p<0.001) and higher GMAX muscle force (rs=0.579; p=0.012) in the 
 
20 control group only. Individuals with PFJ OA (n=60) walked with lower GMED and GMIN muscle forces than 
 
21 controls (n=18): GMED, mean difference 0.15 [95% confidence interval: 0.01 to 0.29] body weight (BW); 
 
22 GMIN, 0.03 [0.01 to 0.06] BW. No between-group differences were observed in VASTI or GMAX muscle 
 
23 force: VASTI, 0.10 [-0.11 to 0.31] BW; GMAX, 0.01 [-0.11 to 0.09] BW. 
 
24 
 
25 Conclusion 
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1 Individuals  with  PFJ  OA  ambulate  with  lower  peak  hip  abductor  muscle  forces  than  their  healthy 
 
2 counterparts. 
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1 INTRODUCTION 
 
2 Patellofemoral joint (PFJ) osteoarthritis (OA) is a common disease, affecting approximately two thirds of 
 
3 those with symptomatic knee OA [1, 2]. Importantly, the PFJ is also a major source of knee pain and 
 
4 reduced physical function [2], exceeding the contribution from the tibiofemoral joint [3, 4]. Despite its 
 
5 prevalence  and  associated  morbidity,  little  is  known  about  the  features  of  people  with  PFJ  OA.  The 
 
6 biomechanics of the PFJ are distinct from the tibiofemoral joint and hence, interventions that have been 
 
7 designed to reduce pain and improve function in those with tibiofemoral disease may be inappropriate for 
 
8 those with predominant PFJ OA. Given the heterogeneity of aetiology, symptomatic presentation and 
 
9 natural history of knee OA, it appears as though optimal interventions should consider targeting the salient 
 
10 features associated with the compartmental involvement [5]. The local PFJ biomechanics, and in particular 
 
11 alignment of the patella within the femoral trochlea, is associated with PFJ OA [6, 7] and its progression [8]. 
 
12 Consequently,  the  few  trials  that  evaluated  targeted  interventions  for  PFJ  OA  focused  on  addressing 
 
13 patellar alignment via passive techniques such as taping [6, 9] and bracing [10]. Such treatments resulted in 
 
14 positive immediate effects, but limited longer-term effects. It is possible that individuals exhibit more 
 
15 global impairments (e.g., thigh and hip muscle dysfunction) that should also be addressed in targeted 
 
16 interventions. 
 
17 
 
 
18 While there is a dearth of information on thigh and hip muscle dysfunction in PFJ OA, similarities in pain 
 
19 characteristics and the likely relationship between PFJ pain syndrome and incident PFJ OA imply that 
 
20 analogies may be drawn from the greater body of knowledge in PFJ pain syndrome. Impairments in hip 
 
21 muscle strength, specifically abduction, extension and external rotation, are features of individuals with PFJ 
 
22 pain syndrome [11]. Furthermore, quadriceps weakness, measured via dynamometry, has been identified 
 
23 as a feature of PFJ OA [12] and is associated with progression of OA in the PFJ [13]. The PFJ is intimately 
 
24 related to  quadriceps function and consequently, individuals exhibiting pain arising from the PFJ  may 
 
25 modify their walking behaviour in order to reduce quadriceps force [14]. However, it is not known whether 
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1 individuals  with  PFJ  OA  ambulate  with  lower  quadriceps  and  hip  muscle  forces  than  their  healthy 
 
2 counterparts. 
 
 
3 
 
4 Biomechanical  evaluations  of  people  with  PFJ  pain  syndrome  are  frequently  performed  to  identify 
 
5 impairments  in  gait.  While  many  studies  have  calculated  net  joint  torques  and  powers  to  evaluate 
 
6 biomechanical  load,  such  measures  do  not  provide  quantitative  information  about  the  function  of 
 
7 individual muscles. Computational musculoskeletal modelling [15] may be used to estimate muscle forces 
 
8 during activities such as gait. Therefore, the aims of this study were to (i) assess whether higher vasti 
 
9 (VASTI),  gluteus  medius  (GMED),  gluteus  maximus  (GMAX)  and  gluteus  minimus  (GMIN)  forces  are 
 
10 associated  with  participant  characteristics  (lower  age,  male  gender)  and  clinical  characteristics  (lower 
 
11 radiographic  disease  severity,  lower  symptom  severity  and  higher  walking  speed);  and  (ii)  determine 
 
12 whether hip and knee muscle forces are lower in people with PFJ OA compared to those without PFJ OA. 
 
13 
 
14 MATERIALS AND METHODS 
 
15 Participants 
 
16 Sixty people with symptomatic PFJ OA and 18 controls (no knee pain and no radiographic OA) participated 
 
17 in this study. People with predominant lateral PFJ OA were a subgroup of a larger cohort recruited for a 
 
18 randomised  controlled  trial  [16]  from  advertisements  in  the  community  and  via  medical  and  health 
 
19 practitioners’ referrals. Inclusion criteria included: (i) aged at least 40 years; (ii) anterior- or retro-patellar 
 
20 knee pain severity ≥ 4 on an 11 point numerical pain scale during at least two activities that load the PFJ 
 
21 (e.g. stair ambulation, squatting and/or rising from sitting); (iii) pain during these activities present on most 
 
22 days during the past month; and (iv) Kellgren and Lawrence (K/L) grading of the lateral PFJ ≥ 2 [17] from 
 
23 skyline views [18] and overall K/L grading (for the tibiofemoral joint) ≤ 2 from postero-anterior views. The 
 
24 control participants were also recruited from the community via advertisements placed in local newspapers 
 
25 and  posters.  They  had  no  knee  or  other  lower-limb  complaints,  were  physically  active  and  had  no 
 
26 radiographic OA (K/L grade ≤ 1 in all compartments). Exclusion criteria included: (i) concomitant pain from 
 
 
5 25-Jun-12 
1 other joints affecting lower-limb function; (ii) recent knee injections (prior 3 months); (iii) body mass index 
 
2 ≥  35  kg.m-2;  (iv)  knee  or  hip  arthroplasty  or  osteotomy;  (v)  physical  inability  to  undertake  testing 
 
3 procedures; (vi) neurological or other medical conditions; and (vii) inability to understand written and 
 
4 spoken English. Participants underwent telephone and physical screening by a single researcher (JL) prior to 
 
5 radiographs. Approval was granted from the University of Melbourne Human Research Ethics Committee, 
 
6 and all participants provided written informed consent. Information on age and gender were collected from 
 
7 the participants and body mass index (BMI) calculated from weight and height measurements. 
 
8 
 
9 Radiographic disease severity 
 
10 Radiographic severity of tibiofemoral joint OA was assessed from a semi-flexed, postero-anterior weight- 
 
11 bearing short film radiograph with the feet externally rotated by 10° using the K/L grading system [17]. 
 
12 Radiographic  severity of PFJ OA  was  assessed  from  weightbearing skyline  radiographs,  with the  knee 
 
13 positioned at 30-40° knee flexion [19], using the K/L grades applied to the PFJ joint[18]. All grading was 
 
14 performed by two investigators (KMC and RSH), with inter-rater reliability (κ) for grading tibiofemoral joint 
 
15 and PFJ radiographic OA on a subset of 39 participants ranging from 0.745-0.843. 
 
16 
 
17 Knee osteoarthritis symptoms 
 
18 The Knee Injury and Osteoarthritis Outcome Score (KOOS) was used to assess patient reported outcomes 
 
19 [20]. The KOOS has five subscales: pain, symptoms, function in activities of daily living (ADL), function in 
 
20 sport and recreation (sport/rec), and knee-related quality of life (QoL). Each of the five subscales addresses 
 
21 symptoms over the previous week, and a normalised score (100 represents no symptoms and 0 represents 
 
22 maximum symptoms) is calculated for each subscale from the original Likert responses. The KOOS is reliable 
 
23 [20] and has face validity for people with PFJ OA symptoms. Thus, in the absence of any PFJ OA-specific 
 
24 outcome measures, the KOOS was deemed to be appropriate for this study. 
 
25 
 
26 Calculation of muscle forces 
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1 A  musculoskeletal  computer  model,  implemented  in  OpenSim  [21],  was  used  to  calculate  lower-limb 
 
2 muscle forces. Estimates of lower-limb muscle forces for walking obtained using this model have been 
 
3 evaluated  previously  [22,  23].  The  skeleton  was  represented  as  an  8-segment,  21-degree-of-freedom 
 
4 linkage (Figure 1A). The head, arms, and torso were modelled as a single rigid body, which articulated with 
 
5 the pelvis via a ball-and-socket back joint. Each hip was modelled as a ball-and-socket joint, and each knee 
 
6 as   a   modified   one-degree-of-freedom   planar   joint.   Each   talo-crural   joint,   subtalar   joint   and 
 
7 metatarsophalangeal joint was modelled as a hinge. The lower limbs and trunk were actuated by 92 
 
8 muscle-tendon units, each represented as a line segment joining an origin point on the proximal segment 
 
9 to an insertion point on the distal segment. The paths of muscles that wrapped over underlying structures 
 
10 were modelled using via points [21]. Each muscle-tendon unit was modelled as a three-element Hill-type 
 
11 muscle  in  series  with  an  elastic  tendon  [24]  (Figure  1B).  For  each  participant,  body-segment  inertial 
 
12 properties and muscle-tendon properties were scaled from a generic adult model [21] using body mass and 
 
13 segment dimensions as scaling factors, respectively. 
 
14 
 
15 Experimental gait data were collected in the Biomotion Laboratory, Department of Mechanical Engineering, 
 
16 University of Melbourne, Australia. Three force plates embedded in the floor of the laboratory were used 
 
17 to record ground reaction forces under both legs at a sampling frequency of 1080 Hz (Advanced Mechanical 
 
18 Technology Inc., Watertown, MA, USA). All ground reaction force data were low-pass filtered using a 
 
19 fourth-order Butterworth filter with a cut-off frequency of 60 Hz. Kinematic data were recorded using a 
 
20 video-based, motion capture system (Vicon, Oxford Metrics, Oxford, UK) with nine cameras sampling at a 
 
21 frequency of 120 Hz. Reflective markers were attached at specific locations on the patient’s trunk, pelvis, 
 
22 both upper limbs and both lower limbs; specifically at the C7 spinous process, acromioclavicular joint, 
 
23 lateral  elbow  epicondyle,  dorsal  aspect  of  the  wrist,  anterior  superior  iliac  spine,  mid-point  between 
 
24 posterior superior iliac spines, anterior mid and distal thigh, lateral mid and distal thigh, lateral femoral 
 
25 epicondyle, proximal and distal anteromedial shank, mid lateral shank, heel, lateral malleolus, lateral and 
 
26 medial  midfoot,  medial  aspect  of  first  metatarsal-phalangeal  joint,  lateral  aspect  of  fifth  metatarsal- 
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1 phalangeal joint, and dorsal aspect of first toe. Muscle electromyographic (EMG) data were collected to 
 
2 enable evaluation of the temporal consistency between muscle force estimates and muscle activations 
 
3 during walking. The EMG data were recorded using pairs of Ag/AgCl surface electrodes (Motion Laboratory 
 
4 Systems, Baton Rouge, LA, USA) mounted on the skin over the gluteus maximus, gluteus medius, medial 
 
5 and lateral vasti, hamstrings, rectus femoris, gastrocnemius and soleus. EMG data were sampled at 1080 
 
6 Hz. The raw EMG signal was full-wave rectified and a Teager-Kaiser Energy (TKE) filter was then applied to 
 
7 the rectified EMG signal to improve the onset and offset detection [25]. Cross-talk was minimised by 
 
8 following published recommendations regarding the placement of surface electrodes [26]. 
 
9 
 
10 An initial static trial was performed with the participant standing in a neutral pose and additional markers 
 
11 placed on the left and right medial femoral epicondyles and medial malleoli. Following the static trial, 
 
12 participants performed three gait trials at a self-selected speed on a 10 m level walkway. Each participant’s 
 
13 walking speed was calculated from the kinematic data by measuring the average horizontal velocity of a 
 
14 marker mounted on the posterior aspect of the pelvis. 
 
15 
 
16 A  single  representative  gait  trial  for  each  participant  was  chosen  for  analysis,  and  all  analyses  were 
 
17 performed in OpenSim [21]. An inverse kinematics problem was solved to determine the model joint angles 
 
18 that best matched the marker data obtained from the gait analysis experiment [27]. The net joint torques 
 
19 were calculated using a traditional inverse dynamics approach [28]. A static optimization problem was then 
 
20 solved to decompose the joint torques into individual muscle forces by minimizing the sum of the squares 
 
21 of the muscle activations [29, 30]. The optimization solution was constrained to the force-length-velocity 
 
22 surface of each muscle [30] (Figure 1C). 
 
23 
 
24 The lower-limb muscle forces of interest were: (1) GMAX; (2) GMED; (3) GMIN; and VASTI (vastus lateralis, 
 
25 intermedius and medialis combined). For each muscle group, peak force during the stance phase was 
 
26 identified and then normalised to the participant’s body weight (BW). 
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1 
 
2 Statistical analysis 
 
3 All analyses were performed using the Statistical Package for the Social Sciences (PASW Statistics 18, SPSS 
 
4 Inc.,  Chicago,  IL)  with  an  alpha  level  of  0.05.  Between-group  differences  in  participant  and  clinical 
 
5 characteristics were assessed using  Student’s  t-tests or chi square tests, as appropriate. The associations 
 
6 between mean peak muscle forces with participant and clinical characteristics were mostly conducted using 
 
7  P earso n’s  r  co rrelatio n  coefficient.  Fo r  the  radio graphic  disease  sev erity  (o rdinal  data),  the   
asso ciatio ns  
 
8 were calculated with the Spearman’s  rho  co rr elation coefficients, while independent t-test were used 
for 
 
9 gender. Between-group differences in mean peak muscle forces were analysed with walking-speed as a 
 
10 covariate using an Analysis of Covariance (ANCOVA). The sample size (60 PFJ OA patients and 18 controls) 
 
11 provides >90% power to detect a between-group difference in muscle force of 10%, with a standard 
 
12 deviation of 10%. 
 
13 
 
14 RESULTS 
 
15 There were no statistically significant differences for age, height or gender between the PFJ OA group 
 
16 (N=60) and the control group (N=18) (Table 1). Those with PFJ OA were heavier than the control individuals, 
 
17 with a greater BMI. In line with our eligibility criteria, the most prevalent radiographic grade (Table 2) was 
 
18 K/L grade 2 in the lateral PFJ and in the tibiofemoral joint. 
 
19 
 
20 Self-selected walking speed was not different between the PFJ OA group and the control group (mean 
 
21 difference [95% confidence interval]: 0.03 [-0.04 to 0.11]) (Table 1). However in the control group, walking 
 
22 speed was significantly correlated with VASTI (r=0.727; p=0.001) and GMAX (r=0.593; p=0.009) peak forces, 
 
23 but age was not statistically significantly correlated with peak muscle forces (Table 3). In the PFJ OA group, 
 
24 walking  speed was  significantly  correlated  with  VASTI peak  force (r=0.495; p<0.001),  but  age  did not 
 
25 statistically significantly correlate with peak muscle forces (Table 3). There was no significant effect of 
 
26 gender on VASTI (0.12: [-0.11 to 0.34], GMAX (-0.03: [-0.12 to 0.06]), GMED (-0.05: [-0.18 to 0.08]) or GMIN 
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1 (-0.01: [-0.03 to 0.02]) peak muscle force. Radiographic disease severity in the tibiofemoral joint and lateral 
 
2 PFJ were not statistically significantly correlated with peak muscle forces in the PFJ OA group (Table 3). 
 
3 Additionally, no statistically significant correlations were observed between any subscale of the KOOS and 
 
4 peak muscle forces in the PFJ OA group (Table 3). 
 
5 
 
6 There were differences in the peak muscle forces for GMED and GMIN between the PFJ OA group and 
 
7 control  group  (Table  4  and  Figure  2).  Individuals  with  PFJ  OA  walked  with  lower  GMED  (0.15  [95% 
 
8 confidence interval: 0.01 to 0.29] BW); and GMIN (0.03 [0.01 to 0.06] BW) muscle forces than controls. No 
 
9 between-group differences were observed in VASTI or GMAX muscle force: VASTI, 0.10 [-0.11 to 0.31] BW; 
 
10 GMAX, 0.01 [-0.11 to 0.09] BW. Ensemble averages across the stance phase of gait for normalised muscle 
 
11 forces are presented in Figure 2. Model predictions of muscle forces were in temporal agreement with 
 
12 measured  EMG  activity  (Supplementary  Figure  1),  providing  a  qualitative  evaluation of  the  modelling 
 
13 approach used in this study. 
 
14 
 
15 DISCUSSION 
 
16 Awareness of the importance of the PFJ in the clinical picture of knee OA is increasing due to its prevalence 
 
17 and contribution to  knee OA  symptoms.  Knowledge  of  impairments associated  with  this subgroup of 
 
18 people with knee OA will advance our understanding of this chronic disease. We found that people with PFJ 
 
19 OA  walk  with  reduced  hip  abductor  muscle  forces,  compared  with  pain-free,  aged-matched  controls. 
 
20 Specifically, peak GMED and GMIN muscle forces were approximately 11% lower than pain-free individuals. 
 
21 The variability in GMAX, GMED, GMIN and VASTI peak muscle forces was not related to radiographic 
 
22 disease severity, knee osteoarthritis symptom severity or other participant characteristics. 
 
23 
 
24 To our knowledge, this is the first study to estimate lower-limb muscle forces in a cohort of people with PFJ 
 
25 OA. Our calculated peak VASTI muscle force was higher (1.16 [95% confidence interval 1.06 to 1.26] BW) 
 
26 than those reported for a single TKA patient walking with an instrumented knee (0.73 BW)  [22]. The 
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1 temporal patterns of lower-limb muscle forces were similar between the two studies. Since walking speed 
 
2 is known to influence the magnitude of lower-limb muscle forces [15], it is possible that differences in 
 
3 walking speed between the current study (1.37 [1.30 to 1.44] m.s-1  , Table 1) and that of Kim et al. [22] 
 
4 (1.24 (standard deviation 0.33) m.s-1) partially explain some of the differences observed in the calculated 
 
5 values of muscle forces. Furthermore, in the study by Kim and colleagues [22], the patient had end stage 
 
6 OA warranting a total joint replacement, whereas our study contained individuals with no greater than K/L 
 
7 grade 2 radiographic OA. Thus, differences in peak VASTI force may be partially accounted for by the 
 
8 disparity in the patient population. It is difficult to directly compare our data with that from a previous 
 
9 study [31], where lower-limb muscle forces were computed for a cohort of younger individuals with PFJ 
 
10 pain syndrome, because an EMG-driven modelling approach was used and all muscle force data were 
 
11 normalised by the peak isometric force of each muscle. 
 
12 
 
13 Our finding of lower peak GMED and GMIN forces in those with PFJ OA is consistent with emerging 
 
14 evidence that hip muscle dysfunction is a dominant feature of individuals with PFJ pain syndrome [11]. The 
 
15 GMED and GMIN primarily contribute to hip abduction moments during walking [32]. Since the cross- 
 
16 sectional nature of the study design precludes knowledge of the temporal relationship between lower 
 
17 GMED and GMIN muscle forces and PFJ OA development or progression, further studies are required to 
 
18 confirm the clinical implications of our findings. Our results indicate that individuals with PFJ OA exhibit 
 
19 altered function that is isolated to the more proximal segments, providing further evidence for a potential 
 
20 link to PFJ pain syndrome. 
 
21 
 
22 We found no difference in peak VASTI and GMAX muscle force in those with and without PFJ OA. Our 
 
23 results contrast with previous studies that have measured peak isometric knee-extensor torque using a 
 
24 dynamometer  [12,  13];  however,  there  is  an  imprecise  relationship  between  knee-extensor  torque 
 
25 measured in an open-kinetic-chain task and peak muscle force utilised during a functional activity such as 
 
26 walking. Our results may reflect variability in gait adaptations during walking in our population of people 
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1 with symptomatic PFJ OA. Notably, there was a non-significant lower peak VASTI muscle force (~8%) in our 
 
2 PFJ OA patients, which may reflect that some individuals are likely to walk with lowered VASTI force, 
 
3 potentially as a pain-relieving strategy. It is also possible that deficits in the coordination (e.g. onset timing) 
 
4 of the medial and lateral components of the vasti may be more important than the total peak VASTI force 
 
5 in individuals with PFJ OA, in a similar manner to PFJ syndrome [33]. Future studies might evaluate VASTI 
 
6 and GMAX muscle forces in functional tasks, such as stair ambulation, which subject the PFJ to greater load, 
 
7 or evaluate the relative coordination of the medial and lateral vasti. 
 
8 
 
9 Peak muscle  forces  were mostly  not  correlated with  participant,  symptomatic  or  radiographic-specific 
 
10 characteristics, implying that muscle forces alone do not reflect the severity of radiographic or symptomatic 
 
11 disease. Although previous investigations of individuals with predominantly tibiofemoral joint OA have 
 
12 observed associations between radiographic OA severity and kinematics at the hip [34], these observations 
 
13 were only significant for those with severe radiographic OA (K/L grade 4). Similarly, many authors have 
 
14 noted a difference in the knee adduction moment only in those with more severe radiographic tibiofemoral 
 
15 disease [35]. It appears likely that changes in gait mechanics at the knee may be associated with the 
 
16 structural changes that accompany the OA disease process, such as altered frontal plane alignment. Since 
 
17 our cohort was restricted to those with a K/L grade ≤ 2, it is not surprising that radiographic disease severity 
 
18 was not associated with peak muscle loading during gait. Although faster walking speed was associated 
 
19 with a higher peak VASTI muscle force in the PFJ OA and control groups and a higher peak GMAX muscle 
 
20 force in the control group, walking speed was controlled for statistically and therefore the between-group 
 
21 differences in muscle force noted in the current study were not attributable to differences in walking 
 
22 speed. 
 
23 
 
24 It is not possible to discern the function of individual muscles from net joint torques alone, simply because 
 
25 a given joint torque can be satisfied by an infinite combination of muscle forces. Musculoskeletal modelling 
 
26 represented the only practicable method for determining lower-limb muscle forces in the current study. 
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1 However, there are several limitations and assumptions inherent in this modelling approach; for example, 
 
2 the physiological properties prescribed for the muscle-tendon actuators included in the model (e.g., peak 
 
3 isometric muscle force and the corresponding muscle-fiber length and tendon rest length; see Figure 1B). 
 
4 Importantly, the present study assumed the same unscaled muscle-tendon parameters across both the PFJ 
 
5 OA and control population and hence, any relative differences in muscle force predictions are attributable 
 
6 mostly to differences in the experimental gait data and not the parameters assumed in the model. We also 
 
7 elected to analyse synergistic groups of muscles (i.e., GMAX, GMED, GMIN, VASTI) and did not attempt to 
 
8 partition calculated forces onto the various components of these muscle groups (e.g., vastus medialis vs 
 
9 intermedius vs lateralis within VASTI). Several studies have shown that our approach of obtaining muscle 
 
10 force estimates for synergistic groups of muscles is relatively insensitive to changes in the values assumed 
 
11 for peak isometric muscle force (or physiological cross-sectional area) [36-38]. Despite the aforementioned 
 
12 limitations, the inverse-dynamics-based optimisation approach employed in the current study is robust, 
 
13 computationally efficient, and has been used extensively to estimate lower-limb muscle forces in walking 
 
14 [15, 39, 40]. Furthermore, indirect evidence is available to support the validity of predicting lower-limb 
 
15 muscle forces during walking using the approach taken in the present paper [22]. Lastly, previous studies 
 
16 have shown temporal agreement between predicted lower-limb muscle forces and recorded EMG [41], and 
 
17 this relationship was also demonstrated in the present study for a representative subject (Supplementary 
 
18 Figure 1). 
 
19 
 
20 A final limitation relates to the participant characteristics of the control group. Although we attempted to 
 
21 recruit participants who were matched on variables likely to influence muscle forces, the control group was 
 
22 lighter and trending towards being younger. We controlled for body weight by normalising all muscle force 
 
23 data, and age was not associated with the muscle force data. In order to be included in the control group, 
 
24 participants had to exhibit a K/L grade ≤ 1. While this is usually accepted as a criterion for no OA, it is 
 
25 possible that participants in the control group had some early/mild OA that may have affected their gait 
 
26 pattern. It is also possible that some participants in either group may have had coexisting hip OA. However, 
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1 the control group were required to have no knee pain and all participants were required to report no 
 
2 hip/groin or lower-back symptoms. The sample size for the control group was chosen to be as large as 
 
3 could be practically achieved within the time and resource constraints, and consequently the control group 
 
4 included much fewer participants (N=18) than our PFJ OA cohort (N=60). This difference reflected the 
 
5 difficulties in recruiting an older population from the general community with no knee or other lower-limb 
 
6 complaints, who were physically active with no radiographic knee OA, and who had the time and inclination 
 
7 to attend for both radiographic and biomechanical evaluation. Nevertheless, our sample size calculations 
 
8 revealed that we had sufficient power, despite the discrepant sample sizes. 
 
9 
 
10 This study is the first to investigate the walking mechanics of individuals with predominant PFJ OA. Our 
 
11 findings indicate that individuals with PFJ OA ambulate with lower peak hip abductor muscle force than 
 
12 their healthy counterparts. It is not known whether a lower hip abductor muscle force contributes to, or is 
 
13 a consequence of, the PFJ OA disease process. 
 
14 
 
15 
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1 Table 1: Participant and clinical characteristics: patellofemoral osteoarthritis and control groups 
 
 Pain-free 
 
Control † 
 
N = 18 
Patellofemoral 
 
osteoarthritis † 
 
N = 60 
Mean difference 
 
[95% CI] 
p value 
Age (yr) 53 (7) 58 (10) 4 [-0.8 to 10] 0.096 
 
Height (m) 
 
1.65 (0.08) 
 
1.69 (0.09) 
 
0.03 [-0.06 to 0.08] 
 
0.186 
 
Weight (kg) 
 
66 (12) 
 
78 (13) 
 
12 [5 to 19] 
 
0.001* 
BMI (kg.m-2) 
 
24.1 (3.4) 
 
27.5 (3.7) 
 
3.3 [1.4 to 5.3] 
 
0.001* 
 
Gender (n(%)) 
 
14 female (78%) 
 
39 female (65%) 
 
- 
 
‡0.236 
 
KOOS-pain 
 
- 
 
63 (15) 
 
- 
 
- 
 
KOOS-symptoms 
 
- 
 
61 (16) 
 
- 
 
- 
 
KOOS-ADL 
 
- 
 
70 (16) 
 
- 
 
- 
 
KOOS-Sport/Rec 
 
- 
 
41 (22) 
 
- 
 
- 
 
KOOS-QoL 
 
- 
 
12 (16) 
 
- 
 
- 
Walking speed (m.s-1) 
 
1.34 (0.13) 
 
1.37 (0.17) 
 
0.03 [-0.04 to 0.11] 
 
0.369 
2 † all values are mean (SD) unless indicated; CI = confidence interval; ‡ χ2; * Denotes statistically significant, p < 0.05 
 
3 BMI = body mass index 
 
4 KOOS = Knee Injury and Osteoarthritis Outcome Score [20] (100 =no symptoms - 0 = maximum symptoms) 
 
5 KOOS-pain = pain subscale of the KOOS 
 
6 KOOS-symptoms =symptoms subscale of the KOOS 
 
7 KOOS-ADL = activities of daily living subscale of the KOOS 
 
8 KOOS-Sport/Rec =Sport and recreation subscale of the KOOS 
 
9 KOOS-QoL =Knee-related quality of life subscale of the KOOS 
 
10 
 
11 
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1 Table 2: Radiographic disease severity for the patellofemoral osteoarthritis group (n = 60) 
 
Grade 0 
 
n (%) 
Grade 1 
 
n (%) 
Grade 2 
 
n (%) 
Grade 3 
 
n (%) 
Grade 4 
 
n (%) 
 
Tibiofemoral (K/L) 14 (23%) 18 (30%) 28 (47%) 0 0 
 
Lateral patellofemoral (K/L)† 0 0 39 (65%) 11 (18%) 10 (17%) 
 
2 K/L Kellgren and Lawrence scale [17]: 0 = no osteoarthritis ; 4 = severe osteoarthritis 
 
3 K/L† Kellgren and Lawrence scale adapted for patellofemoral joint [18] 
 
4 
 
5 
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1 Table  3:  Univariate  associations  between  normalised  peak  muscle  forces,  participant  and  clinical 
 
2 characteristics 
 
GMAX GMED GMIN VASTI 
 
Control group (n=18) 
 
Age (yr) r -0.195 -0.96 -0.84 106 
 
p 0.439 0.705 0.739 0.676 
 
Walking speed (m.s-1) r 0.593 0.076 0.047 0.727 
 
p 0.009* 0.764 0.853 0.001* 
 
PFJ OA group (n=60) 
 
Age (yr) R -0.86 -0.138 -0.125 -0.174 
 
P 0.514 0.295 0.340 0.185 
 
KOOS-pain R 0.081 0.050 0.023 0.103 
 
p 0.539 0.704 0.859 0.435 
 
KOOS-symptoms  r -0.026 -0.029 -0.041 0.069 
 
p 0.843 0.826 0.754 0.598 
 
KOOS-ADL r -0.045 -0.053 -0.062 0.133 
 
p 0.734 0.685 0.637 0.311 
 
KOOS-Sport/Rec  r -0.018 -0.050 -0.056 0.261 
 
p 0.892 0.702 0.669 0.097 
 
KOOS-QoL r -0.059 -0.036 -0.029 0.111 
 
p 0.652 0.784 0.824 0.396 
 
Walking speed (m.s-1) r 0.145 0.090 0.040 0.495 
 
p 0.267 0.494 0.763 <0.001* 
 
Tibiofemoral (K/L)‡ rho -0.040 0.114 0.108 0.058 
 
p 0.763 0.385 0.413 0.660 
 
Lateral patellofemoral (K/L) ‡† rho -0.084 0.104 0.060 -0.072 
 
p 0.524 0.430 0.649 0.586 
 
3 Correlations using Pearson’s r correlation co-efficient unless indicated 
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1 ‡Correlations using Spearman’s rho correlation co-efficient * Denotes statistically significant, p < 0.05 
 
2 GMAX = gluteus maximus 
 
3 GMED = gluteus medius 
 
4 GMIN= gluteus minimus 
 
5 VASTI = vastus medialis, vastus lateralis and vastus intermedialis 
 
6 KOOS = Knee Injury and Osteoarthritis Outcome Score [20] (100=no symptoms – 0=maximum symptoms) 
 
7 KOOS-pain = pain subscale of the KOOS 
 
8 KOOS-symptoms =symptoms subscale of the KOOS 
 
9 KOOS-ADL = activities of daily living subscale of the KOOS 
 
10 KOOS-Sport/Rec =Sport and recreation subscale of the KOOS 
 
11 KOOS-QoL =Knee-related quality of life subscale of the KOOS 
 
12 K/L Kellgren and Lawrence scale [17]: 0 = no osteoarthritis ; 4 = severe osteoarthritis 
 
13 K/L† Kellgren and Lawrence scale adapted for patellofemoral joint [18] 
 
14 
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1 Table 4: Between group comparisons of normalised peak muscle forces between symptomatic PFJ OA 
 
2 and control groups 
 
Pain-free 
 
Control † 
 
N = 18 
Patellofemoral 
 
osteoarthritis † 
 
N = 60 
Mean difference † P 
 
GMAX (BW) 0.69 [0.61 to 0.78] 0.70 [0.66 to 0.75] 0.01 [-0.11 to 0.09] 0.796 
 
GMED (BW) 1.41 [0.28 to 1.53] 1.26 [1.19 to 1.33] 0.15 [0.01 to 0.29] 0.041* 
GMIN (BW) 0.24 [0.22 to 0.26] 0.21 [0.20 to 0.22] 0.03 [0.01 to 0.06] 0.013* 
VASTI (BW) 1.26 [1.08 to 1.44] 1.16 [1.06 to 1.26] 0.10 [-0.11 to 0.31] 0.355 
 
3 † all values are mean *95% confidence interval+ and adjusted for walking speed; * Denotes statistically significant, p < 
 
4 0.05 
 
5 BW = body weight 
 
6 GMAX = gluteus maximus 
 
7 GMED = gluteus medius 
 
8 GMIN= gluteus minimus 
 
9 VASTI = vastus medialis, vastus lateralis and vastus intermedialis 
 
10 
 
11 
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